Sana Biotechnology, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report; standalone fourth-quarter financial results are not clearly provided in the filing text. Sana is a clinical-stage cell-engineering company with no products approved for sale and no product revenue.
Business context and pipeline
Sana’s strategy centers on engineered cell therapies, particularly its hypoimmune (HIP) platform, intended to help allogeneic cells evade immune rejection. In October 2023, the company shifted resources toward ex vivo cell therapies and reduced near-term investment in its in vivo fusogen platform.
- SC291: Phase 1 ARDENT trial in B-cell malignancies; also being evaluated in the GLEAM autoimmune-disease trial.
- SC262: Phase 1 VIVID trial for B-cell malignancies following prior CD19 CAR T therapy.
- UP421: Investigator-sponsored first-in-human study of HIP-modified primary islet cells in type 1 diabetes.
- SC255: Preclinical BCMA CAR T program, gated by resource availability. SC451 is a preclinical stem-cell-derived islet program; SC379 is a glial progenitor program, with clinical testing targeted as early as 2025.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | None from product sales | None from product sales |
| Research and development expense | $268.8 million | $285.9 million |
| General and administrative expense | $73.3 million | $71.6 million |
| Total operating expenses, net of fair-value gains | $293.1 million | $272.6 million |
| Loss from operations | $293.1 million | $272.6 million |
| Net loss | $283.3 million | $269.5 million |
| Net loss per share, basic and diluted | $1.46 | $1.43 |
| Net cash used in operating activities | $253.6 million | $290.1 million |
Net loss increased about 5% year over year, while operating cash use declined. R&D expense fell about 6%, partly reflecting reprioritization; the decrease was partly offset by a $7.0 million impairment of lab equipment and leasehold improvements. The company reported no product revenue, so gross margin is not applicable. Interest income, net, rose to $9.9 million from $3.8 million.
- At year-end, cash, cash equivalents, and marketable securities totaled $205.2 million; total cash, cash equivalents, and restricted cash were $137.3 million. Sana reported no debt outstanding.
- Management said year-end liquidity was expected to fund working capital and capital expenditures for at least 12 months, based on current plans and assumptions. The company expected 2024 operating cash burn below $200 million following the repositioning.
- In February 2024, after year-end, Sana raised approximately $179.9 million net in an offering of 21.8 million common shares and pre-funded warrants for 12.7 million shares. This provides additional liquidity but dilutes shareholders.
- Undiscounted operating lease payments totaled $200.5 million; recorded lease liabilities were $104.1 million. Contingent consideration was $109.6 million and success-payment liabilities were $12.8 million at year-end. These obligations are distinct from debt.
Material changes, outlook, and risks
- Strategic repositioning: The October 2023 move prioritized ex vivo programs, delayed the SG299 IND submission, and reduced the workforce by approximately 29%. Sana recorded $5.2 million in cash-based severance and related costs; the repositioning was substantially complete by year-end. Management expected 2024 operating expenses to decrease, excluding potential one-time items.
- Early clinical data: In January 2024, Sana reported interim ARDENT data: six patients had been dosed and four were evaluable. Three of the four had at least a partial response, including two ongoing complete responses at the reported follow-up points. No dose-limiting toxicities, SC291-related serious adverse events, graft-versus-host disease, any-grade CRS or ICANS, or Grade 3-or-higher infections were reported among those four evaluable patients. These are preliminary, small-sample results, not evidence of established efficacy or safety.
- Near-term milestones: Sana expected additional ARDENT data and data or progress updates from GLEAM, VIVID, and the UP421 investigator-sponsored study during 2024. These plans are forward-looking and subject to clinical, regulatory, enrollment, and manufacturing risks.
- Key risks: The platforms and product candidates are novel and unproven; clinical outcomes and regulatory pathways are uncertain. Manufacturing scale-up, CDMO and donor-material supply, patient enrollment, safety—including gene-editing and CAR T risks—and reliance on licensed intellectual property could delay or prevent development. Sana expects continued losses and anticipates needing additional financing; future capital may be unavailable on acceptable terms.
- Other financial considerations: Fair-value changes in contingent consideration and success-payment liabilities materially affect reported expenses and can be volatile and non-cash. The company also disclosed inflation, geopolitical and market risks. It reported no material legal proceedings.
Important facts for investors to verify
- Confirm current cash, cash burn, and runway after the February 2024 offering; compare actual subsequent spending with management’s under-$200-million 2024 burn expectation.
- Track enrollment, follow-up duration, response definitions, adverse events, and full results from ARDENT; assess whether the early findings persist in larger patient numbers and at higher doses.
- Check the timing and results of GLEAM, VIVID, and UP421 updates, and whether any planned clinical or regulatory milestones have changed.
- Monitor manufacturing-facility build-out, CDMO capacity, supply reliability, and related lease and capital commitments.
- Review future dilution and the terms or triggers for the Cobalt contingent consideration and Harvard and Cobalt success-payment obligations.
- Note that the financial statements received an unqualified audit opinion from Ernst & Young LLP. Management reported effective internal control over financial reporting, but the auditor did not provide an attestation because Sana qualified as an emerging growth company.